Zomedica Corp. ZOM
We take great care to ensure that the data presented and summarized in this overview for Zomedica Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ZOM
View all-
Vanguard Group Inc Valley Forge, PA48.3MShares$8.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA10.1MShares$1.82 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.86MShares$1.78 Million0.0% of portfolio
-
State Street Corp Boston, MA3.11MShares$559,9040.0% of portfolio
-
Brown Brothers Harriman & CO New York, NY2.47MShares$443,9750.0% of portfolio
-
Northern Trust Corp Chicago, IL1.8MShares$323,7090.0% of portfolio
-
Atom Investors LP Austin, TX1.2MShares$216,1880.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD948KShares$170,6940.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il743KShares$133,7590.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA412KShares$74,2200.0% of portfolio
Latest Institutional Activity in ZOM
Top Purchases
Top Sells
About ZOM
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Insider Transactions at ZOM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 17
2024
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
100,000
+2.22%
|
$0
$0.18 P/Share
|
|
May 16
2024
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
25,000
+1.16%
|
$0
$0.18 P/Share
|
|
May 14
2024
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
50,000
+1.18%
|
$0
$0.14 P/Share
|
|
May 13
2024
|
Anthony K Blair COO |
BUY
Open market or private purchase
|
Direct |
150,000
+50.0%
|
$0
$0.14 P/Share
|
|
May 13
2024
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
100,000
+4.65%
|
$0
$0.14 P/Share
|
|
May 13
2024
|
Larry C Heaton Ii CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+25.0%
|
$0
$0.14 P/Share
|
|
Dec 15
2023
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
100,000
+98.09%
|
$0
$0.16 P/Share
|
|
Nov 17
2023
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
100,000
+5.13%
|
$0
$0.17 P/Share
|
|
Nov 17
2023
|
Larry C Heaton Ii CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+33.33%
|
$0
$0.17 P/Share
|
|
Nov 15
2023
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
150,000
+7.89%
|
$0
$0.17 P/Share
|
|
May 26
2023
|
Larry C Heaton Ii CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+50.0%
|
$0
$0.19 P/Share
|
|
May 25
2023
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
100,000
+5.88%
|
$0
$0.19 P/Share
|
|
Nov 18
2021
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
250,000
+14.29%
|
$0
$0.45 P/Share
|
|
Jun 30
2021
|
Robert Cohen |
SELL
Open market or private sale
|
Direct |
543,750
-100.0%
|
$0
$0.82 P/Share
|
|
Jun 30
2021
|
Robert Cohen |
BUY
Exercise of conversion of derivative security
|
Direct |
543,750
+50.0%
|
$0
$0.23 P/Share
|
|
Jun 15
2021
|
Johnny D Powers |
SELL
Open market or private sale
|
Direct |
125,000
-9.09%
|
$0
$0.93 P/Share
|
|
Jun 15
2021
|
Johnny D Powers |
BUY
Exercise of conversion of derivative security
|
Direct |
125,000
+8.33%
|
$0
$0.26 P/Share
|
|
Jun 01
2021
|
Robert Cohen |
SELL
Open market or private sale
|
Direct |
3,193,750
-100.0%
|
$0
$0.81 P/Share
|
|
Jun 01
2021
|
Robert Cohen |
BUY
Exercise of conversion of derivative security
|
Direct |
3,193,750
+38.6%
|
$0
$0.21 P/Share
|
|
May 17
2021
|
Johnny D Powers |
SELL
Open market or private sale
|
Direct |
125,000
-9.09%
|
$0
$0.78 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 975K shares |
|---|